Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.86 |
| ▸ | CHAT | P28329 | 2/20 | 0.82 |
| ▸ | EP300 | Q09472 | 3/20 | 0.81 |
| ▸ | AURKA | O14965 | 2/20 | 0.81 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.81 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.81 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612561 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL120171 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL26135395 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL1533824 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL30411982 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL22609304 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL2935253 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL22612510 | 1.00 | NAA50 (0.86) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL28487648 | 0.98 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 | |
| SCHEMBL30046331 | 0.96 | NAA50 (0.84) | NAA50CHATEP300AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151709-A1 | COMPOSITIONS FOR INDUCING OR RESCUING GLYCOLYSIS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-18 | — | — | WO | claimed |
| US-20230058160-A1 | METABOLITE-BASED POLYMERS, MICROPARTICLES, AND NANOPARTICLES FOR IMMUNOTHERAPY AND METHODS OF TREATING A DISEASE OR DISORDER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2023-02-23 | — | — | US | claimed |
| EP-3731859-B1 | PYRIDAZINE COMPOUNDS FOR USE TO TREAT DISORDERS ASSOCIATED WITH CASTOR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4499817-A1 | BIOSYNTHESIS | Plant Bioscience Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| CN-118742650-A | Production of saponins in yeast | 加利福尼亚大学董事会 | 2024-10-01 | — | — | CN | disclosed |
| WO-2024151709-A1 | COMPOSITIONS FOR INDUCING OR RESCUING GLYCOLYSIS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-118147102-A | Polypeptide for improving avermectin B1a yield and application thereof | 中国农业大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-118147102-A | Polypeptide for improving avermectin B1a yield and application thereof | 中国农业大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4298217-A1 | TISSUE-SPECIFIC METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Flagship Pioneering Innovations VI, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4262814-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | St. Jude Children's Research Hospital, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023180677-A1 | Biosynthesis | PLANT BIOSCIENCE LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| CN-116426454-A | Genetic engineering method for improving titer and proportion of avermectin B1a component | 浙江工业大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-115725665-A | Hyperforin biosynthesis gene cluster and application thereof | 中国科学院分子植物科学卓越创新中心 | 2023-03-03 | — | — | CN | disclosed |
| US-20230058160-A1 | METABOLITE-BASED POLYMERS, MICROPARTICLES, AND NANOPARTICLES FOR IMMUNOTHERAPY AND METHODS OF TREATING A DISEASE OR DISORDER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| EP-4065556-A1 | MACROCYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022183210-A1 | TISSUE-SPECIFIC METHODS AND COMPOSITIONS FOR MODULATING A GENOME | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2022-09-01 | — | — | WO | disclosed |
| WO-2022133034-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058160-A1 | METABOLITE-BASED POLYMERS, MICROPARTICLES, AND NANOPARTICLES FOR IMMUNOTHERAPY AND METHODS OF TREATING A DISEASE OR DISORDER | PC, CD47, CD14 | NAA50 3009/4885CHAT 2224/4885EP300 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.